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Cancer developmentJMJD5 is a Jumonji C domain-containing demethylase/hydroxylase shown to be essential in embryological
development, osteoclastic maturation, circadian rhythm regulation and cancer metabolism. However, its
role and underlying mechanisms in oncogenesis remain unclear. Here, we demonstrate that JMJD5 forms
complex with the tumor suppressor p53 by interacting with p53 DNA-binding domain (DBD), and negatively
regulates its activity. Downregulation of JMJD5 resulted in increased expression of multiple p53 downstream
genes, such as the cell cycle inhibitor CDKN1A and DNA repair effector P53R2, only in p53-proﬁcient lung cancer
cells. Upon DNA damage, the JMJD5–p53 association decreased, and thereby, promoted p53 recruitment to the
target genes and stimulated its transcriptional activity. Furthermore, JMJD5 facilitated the cell cycle progression
in a p53-dependent manner under both normal and DNA damage conditions. Depletion of JMJD5 inhibited cell
proliferation and enhanced adriamycin-induced cell growth suppression in the presence of p53. Collectively,
our results reveal that JMJD5 is a novel binding partner of p53 and it functions as a positive modulator of cell
cycle and cell proliferation mainly through the repression of p53 pathway. Our study extends the mechanistic
understanding of JMJD5 function in cancer development and implicates JMJD5 as a potential therapeutic target
for cancer.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
JMJD5 (also known as KDM8) belongs to an evolutionarily conserved
protein family that contains jumonji C (JmjC) domain. Members of this
family have been characterized as demethylases or hydroxylases and
show crucial functions in various biological processes by targeting histone
andnonhistone proteins [1–4]. Functional studies of JMJD5 reveal that it is
necessary for embryonic development, and has a pivotal role in circadian
rhythm maintenance, osteoclastogenesis, cancer cell metabolism and
proliferation [5–10]. Although initial studies identiﬁed JMJD5 as a classic
histone demethylase processing dimethylated Lys-36 in histone H3
(H3K36me2), some subsequential investigations also demonstrated it as
a hydroxylase toward nonhistone proteins, suggesting a complicated
and context-dependent function of this protein [9,11].
Several studies provide strong evidences that JMJD5 plays an
important role in cell cycle regulation. One of the G1/S and G2/M
transition regulators, CCNA1 gene,was activated to promote breast cancer
cell proliferation by JMJD5 via demethylating H3K36me2 in its coding.
jingwzy@zju.edu.cn (J. Shen).region [5,12]. In addition, JMJD5 was also reported to negatively regulate
the expression of p21, a potent cyclin-dependent kinase inhibitor. In
mouse embryonic cells, the deﬁciency of JMJD5 caused upregulation
of p21, contributing to cell growth retardation, pluripotency loss of
embryonic stem cells, and embryonic lethality [7,8,13]. Given that p21 is
a major target of tumor suppressor p53, the involvement of p53 pathway
in the regulationwas further studied. However, contradictory results have
been reported, and the cross-talk between JMJD5 and p53 still remains
uncertain [7,8].
As a key tumor suppressor protein that has numerous functions, p53
undergoes various post-translational modiﬁcations that may result in
either activation or repression of its activity [14]. Recently, methylation
was considered as a novel mechanism of p53 regulation [15]. Several
histone methyltransferases (e.g., SET8, SET9, and SMYD2) have been
demonstrated to methylate p53 at speciﬁc C-terminal lysines (Lys370,
Lys372, and Lys382) [16–18]. By contrast, only the histone demethylase
LSD1 (lysine-speciﬁc demethylase 1) was identiﬁed hitherto to
mediate p53 demethylation at dimethylated Lys-370, which inhibits
p53 interaction with its co-activator 53BP1 [19]. Whether other histone
demethylases, such as JmjCprotein family, involved in p53 demethylation
and functional regulation is unclear. Interestingly, recent studies reported
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after testing several JmjC-containing histone demethyalses, they detected
interactions between p53 and those proteins [20–23]. With association,
the transcriptional activity and nuclear localization of p53 were ﬁnely
regulated.
Considering the vague understanding of JMJD5 in p53 tumor suppres-
sor pathway and its role as a JmjC domain-containing demethylase,
we therefore aim to determine the ability of JMJD5 in regulating
p53 activity and downstreamgenes in cancer cells.Wehere demonstrate
that JMJD5 negatively regulates the transcriptional activity of p53 through
the association with p53 DBD domain, thus interfering p53 pathway-
dependent cell growth and cell cycle response after DNA damage.
2. Materials and methods
2.1. Cell culture and treatment
Human lung carcinoma A549 and H1299 cells were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal calf serum, penicillin (100 U mL−1) and streptomycin
(100 μg mL−1) at 37 °C, 5% CO2. When cells achieved logarithmic
growth, they were exposed to different concentrations of adriamycin
or MNNG (Sigma) for indicated time. Dimethyl sulfoxide (DMSO) was
used as solvent control.
2.2. Plasmids, transient transfection and immunoblotting
The full length human JMJD5 and TP53were inserted into a pCDNA3.1
vector with a 6 × myc tag (Invitrogen) or a pcDNA3.1-Flag vector.
Deletion fragments were obtained using appropriately designed primers,
and mutants were generated with the QuickChange II site-directed
mutagenesis kit (Stratagene) according to the manufacturer's
instructions. All plasmid constructs were veriﬁed by DNA sequencing.
Transfection of cells was achieved using X-tremeGENE HP DNA Transfec-
tion Reagent (Roche) with similar efﬁciency. After transfection for 48 h,
the cells were lysed in lysis buffer (RIPA, Millipore) and separated in
SDS-PAGE. Proteins were then transferred to nitrocellulose membrane
(Whatman) and incubated with primary antibodies against rabbit
anti-JMJD5 (Abcam ab36104), rabbit anti-p53K372me1 (Abcam
ab16033), rabbit anti-H3 (Abcam ab1791), rabbit anti-H3K36me2
(Abcam ab9049) and H3K36me3 (Abcam ab9050), mouse anti-p53
(sc-126), mouse anti-p21 (sc-6246), mouse anti-GAPDH (sc-32233),
rabbit anti-Myc (sc-789), rabbit anti-actin (sc-7210), and mouse anti-
Flag (Sigma F1804). Membranes were then washed with Tris buffered
saline (TBS), by Alex 680- or IR 800-conjugated secondary antibody
for Odyssey LICOR analysis (Li-COR, Bioscience).
2.3. Chromatin-free and chromatin-bound fractions isolation
Cellular fractionation was carried out as previously reported [24].
Brieﬂy, cells were incubated with the buffer I (1% NP-40, 5 mMMgCl2,
10 mM NaCl, 20 mM Tris (pH 8.0), protease inhibitor cocktail (Roche))
and rotated for 1 h at 4 °C. After incubation, lysates were pelleted at
12,000 g for 10 min, and the chromatin-free supernatant was collected.
The insoluble pellet was further resuspended in buffer II (1% NP-40,
5 mM MgCl2, 150 mM NaCl, 20 mM Tris (pH 8.0), protease inhibitors
cocktail (Roche)), and incubated for 1 h at 4 °C followed by sonication
for solubilization. The extracted fraction contains chromatin-bound
proteins. All fractions were then denatured, separated by SDS-PAGE
and analyzed by immunoblotting.
2.4. Co-immunoprecipitation
For co-immunoprecipitation, cell lysates (0.5–1mg) were incubated
with 1 μg of a primary antibody for 16 h at 4 °C, and then with proteinA/G-agarose beads for 2 h at 4 °C. The bound proteins were denatured
by boiling in Laemmli sample buffer and analyzed by immunoblotting.
2.5. RNA interference (RNAi)
To inhibit JMJD5 expression, two oligonucleotide siRNAs targeting
human JMJD5 (siGENOME KDM8 siRNA-1; 5′-CCACUGAGCUCUUCUA
CGA-3′, and siGENOME KDM8 siRNA-3 5′-UCAACGAGUUCAUCAGCAA-
3′) and a control oligonucleotide siRNA targeting luciferase (5′-CUUACG
CUGAGUACUUCGA-3′) were purchased from Thermo Scientiﬁc. Cells
were transfected with a ﬁnal concentration of 100 nM siRNA using
X-tremeGENE siRNA transfection reagent (Roche) and analyzed after
72 h.
2.6. RNA analysis and ChIP assays
Total RNAwas extractedwith RNAiso Plus reagents (TaKaRa Bio Inc.)
according to the manufacturer's instruction. Quantitative real-time PCR
(qPCR)was performedwith standard procedures using SYBR Premix Ex
Taq (TaKaRa Bio Inc.) on an ABI Prism 7500 real-time PCR system
(Applied Biosystems). β-Actin was used as loading control. Primers
were used as follows: JMJD5, forward, 5′-CCATCAATGCCTGGTTTG
GTC-3′, reverse, 5′-GTGCGTGTCATGAGGGTACAGAG-3′; TP53, forward,
5′-GGTCTGGCCCCTCCTCAGCA-3′, reverse, 5′-TGCCGCCCATGCAGGAAC
TG-3′; CDKN1A, Forward, 5′-CACCGAGACACCACTGGAGG-3′, reverse,
5′-GAGAAGATCAGCCGGCGTTT-3′; SFN, forward, 5′-GGCCATGGACAT
CAGCAAGAA-3′, reverse, 5′-CGAAAGTGGTCTTGGCCAGAG-3′; Gadd45,
forward, 5′-TGCGAGAACGACATCAACAT-3′, reverse, 5′-TCCCGGCAAA
AACAAATAAG-3′; Puma, forword, 5′-GACCTCAACGCACAGTA-3′, reverse,
5′-CTAATTGGGCTCCATCT-3′; Noxa, forward, 5′-AGAGCTGGAAGTCGAG
TGT-3′, reverse, 5′-GCACCTTCACATTCCTCTC-3′; Pig3, forward, 5′-TCTC
TGAAGCAACGCTGAAATTC-3′, reverse, 5′-ACGTTCTTCTCCCAGTAGGA
TCC-3′; p53R2, forward, 5′-TCTCCCTCACTGGAACAAGC-3′, reverse, 5′-
ACCTGCACCTCCTGACTAAA-3′; MDM2, forward, 5′-TACAGGGACGCCAT
CGAATC-3′, reverse, 5′-ATCACTCTCCCCTGCCTGAT-3′.
ChIP assays were carried out with the SimpleChIP Enzymatic
Chromatin IP Kits (Cell Signaling Technology). Antibodies against p53
(Santa Cruz), JMJD5 and H3K36me2 (Abcam) as well as a negative
control, rabbit IgG, were used for ChIP assay. Puriﬁed DNA from cross-
linked cells was dissolved in 30 μL DNA elution reagent; 2 μL was used
for PCR. Inputs consisted of 2% chromatin before immunoprecipitation.
The following primers were used: CDKN1A_RE1, forward, 5′-CAGGAA
CATGCTTGGGCAGCAG-3′, reverse, 5′-CCTTCCTCACCTGAAAACAGG-3′;
CDKN1A_RE2, forward, 5′-GAGGAGAAAGAAGCCTGTCC-3′, reverse,
5′-CCACTAAAAAACAGAACCCAGG-3′; CDKN1A_C, forward, 5′-GAATGA
GAGGTTCCTAAGAG-3′, reverse, 5′-GGACAAGTGGGGAGGAGGAAG-3′;
p53R2_RE, forward, 5′-CTAGATTGGGGCATCGTAAGTGCTTG-3′, reverse,
5′-GACATTCTGCTGTTTTTTCCAGAATG-3′; p53R2_C, forward, 5′-CCAC
CTTTTAAGGGGAGGTGTATCC-3′; reverse, 5′-CTGAAAGATCTCAAGGAG
TAAGAGG -3′.
2.7. Luciferase assay
Cells were seeded at a density of 1 × 105 cells/well in a 24-well plate
the day before transfection. Five-hundred nanogram ﬁreﬂy luciferase
reporter constructs, 0.02 μg of pRL-SV40 Renilla luciferase reporter
plasmids (Promega) and CDKN1A and P53R2 reporter genes were
cotransfected using X-tremeGENE HP DNA Transfection Reagent
(Roche). A dual-luciferase reporter assay system (Promega) was
used to measure the luciferase activity.
2.8. Cell cycle analysis
Cells were transfected with the plasmids for 48 h or siRNA for 72 h,
permeabilized by 70% ethanol at −20 °C for 15 min, and incubated
with 50 μg/mL PI and 20 units/mL RNase-A (Roche). Analysis was
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(Beckman Coulter) and FlowJo 7.6 software.
2.9. Protein puriﬁcation and GST pull-down assay
JMJD5 and JMJD2A were expressed as a His6-tag fusion using the
pET-28b(+) expression vector and p53 as a GST-tag fusion using the
pGEX-4T3 expression vector. All protein coding sequenceswere veriﬁed
by sequencing. Following expression in Rosetta Escherichia coli at 25 °C
induced by 1 mM IPTG when the OD reached 0.5–0.6, proteins were
puriﬁed using glutathione agarose beads (Amersham Biosciences) or
Ni-NTA beads (Qiagen) according to the manufacturer's instructions.
For GST pull-down assay, GST–p53 fusion proteins were bound to
glutathione agarose, and incubated with cell lysate. Then the bound
JMJD5 was detected by immunoblotting.
2.10. In vitro demethylation assay
Cell lysate with Flag–p53 transfection or acid extracted histones
or synthetic peptides (p53me1: SSHLKmeSKKGQSTSRHKKmeLMFK;
p53me2: SSHLKme2SKKGQSTSRHKKme2LMFK; H3K9me3-ab1773,
p53K372me1-ab16203, Abcam) was incubated with puriﬁed His-tagged
JMJD5 or JMJD2A in buffer (150 mM NaCl, 20 mM Tris–HCl pH 8.0,
2 mM ascorbic acid, 1 mM ketoglutarate, and 50 μM (NH4)2Fe(SO4)2) at
37 °C for 2–3 h. Then the demethylation products were enriched and
desalted using a μ-C18 Ziptip (Millipore). Reaction products were
analyzed either by immunoblotting or mass spectrometry.
For mass spectrometry, eluents were directly loaded onto a MALDI
plate containing 2 μL of a CHCA (α-cyano-4-hydroxy cinnamic acid)
saturated solution in 50% acetonitrile (ACN) and 0.1% triﬂuoroacetic
acid (TFA). MALDI-TOF spectra were acquired on a 4700 MALDI
TOF/TOF mass spectrometer (Applied Biosystems).
2.11. In silico docking analysis
In silico docking was performed using ClusPro 2.0 server (http://
cluspro.bu.edu/login.php) [25]. We predicted the interaction of JMJD5
(PDB: 4GJY) with the DBD of p53 (PDB: 2FEJ) from RCSB PDB database
(http://www.rcsb.org/pdb/home.do).
2.12. Statistical analysis
All experiments were performed at least triplicate and are repre-
sentative of at least three independent repeats. Statistical analysis
was performed by one-way ANOVA and the results were regarded
signiﬁcant when P b 0.05. Error bars represent s.d.
3. Results
3.1. JMJD5 knockdown induces upregulation of CDKN1A (p21) and reduction
of cell growth in p53-proﬁcient lung cancer cells
Knockdown of JMJD5 has been shown to negatively regulate the
expression of CDKN1A (p21) in mouse embryonic cells with an uncer-
tain alteration of p53 [7,8]. To examine their changes in cancer cells,
we depleted JMJD5 expression using short interfering RNA (siRNA) in
p53-proﬁcient A549 lung cancer cells. Ablation of JMJD5 resulted in
increased expression of CDKN1A (p21) both in mRNA and protein
level, which was not caused by an enhanced basal level of p53 (Fig. 1A
and B). A luciferase reporter gene was then employed to conﬁrm the
transcriptional change of p21. Compared to the repressed reporter
activity after p53 knockdown, JMJD5 siRNA treatment signiﬁcantly
transactivated the p21 promoter (Fig. 1C). Furthermore, immunostaining
assay of JMJD5 silencing cells showed an increased nuclear localization of
p53, which is known as a key step in p53 activation (Fig. 1D and E). We
next investigate whether the effect of JMJD5 on p21 is p53-dependent.As shown in Fig. 1A and B, the induction of p21 after JMJD5 siRNA
treatment was largely impaired in H1299 cells, which is p53-deﬁcient.
We then analyzed the impact of JMJD5 knockdown on lung cancer cell
growth. A signiﬁcant inhibition was observed after JMJD5 depletion in
p53-proﬁcient but not p53-deﬁcient cells (Fig. 1F). Cell cycle analysis
showed that JMJD5 downregulation caused G2/M arrest, while ectopic
overexpression of JMJD5 reduced the number of G2/M fraction cells
(Fig. 1G). Taken together, these results suggest that JMJD5 exerts its
function in gene regulation and cell proliferation mainly through p53
activation.
3.2. JMJD5 is associated with p53 in cancer cells
Given that JMJD5 has been reported as a demethylase/hydroxylase,
we next evaluated its role in regulating post-translational modiﬁcations
of p53. After analyzing the ability of JMJD5 to demethylate/hydroxylate
p53 peptides encompassing methylated K370, K372 or K382 in vitro,
however, we could not demonstrate such functions (Fig. S1). Similarly,
with the speciﬁc antibody to p53K372me1, we also could not ﬁnd the
inﬂuence of JMJD5 on p53 methylation in vivo and in vitro (Fig. S1).
Since protein–protein interaction is another important regulatory
mechanism in modulating p53 function, we then preformed a
coimmunoprecipitation to examine the association between JMJD5
and p53. Flag-tagged JMJD5 and Myc-tagged p53 were ectopically
coexpressed in HEK293T cells, followed by immunoprecipitation
using anti-Flag or anti-Myc antibodies. Western blotting analysis
revealed that JMJD5 and p53 associated with each other (Fig. 2A
and B). The interaction between endogenous JMJD5 and p53was further
conﬁrmed in A549 cells (Fig. 2C). Moreover, puriﬁed Flag–JMJD5 and
glutathione S-transferase (GST)-tagged p53 from bacteria were used in
GST pull-down assays. We found that GST–p53 speciﬁcally associated
with Flag–JMJD5 (Fig. 2D). Altogether, these results demonstrate that
JMJD5 physically interacts with p53.
To identify theminimal region crucial for the JMJD5–p53 interaction,
we cloned three different fragments of p53 fused to Flag-tag. With
coimmunoprecipitation, the DBD (DNA-binding domain) of p53
was found to interact with JMJD5 (Fig. 3A). With a series of N- and
C-terminal deletion fragments of JMJD5, it was revealed that the region
of amino acids 171–270 between JmjC (271–416) and the nuclear
localization signal (NLS) (152–170) was responsible for the JMJD5–
p53 interaction (Fig. 3B). We then constructed the catalytically inactive
JMJD5 mutants H321A/D323A, K336A and H400A, in which the Fe[II]
and 2-oxoglutarate binding residues were substituted by alanine.
All the mutations showed no effect on the JMJD5–p53 association
(Fig. 3C), demonstrating that the interaction between JMJD5 and p53
does not depend on the enzymatic domain of JMJD5. Furthermore,
beneﬁting from the data obtained from the structures of JMJD5 [11]
and p53 [26], we conducted in silico docking analysis to predict their
physical interactions. The bindingmodel from docking analysis showed
that JMJD5 occupied the DNA binding region of p53 DBD, which
comprises the major (loop L1 and helix H2) and minor groove (loop L2
and L3) binding surfaces [27](Fig. 3D).
3.3. DNA damaging agents reduce the association between JMJD5 and p53
p53 activation is a critical cellular response to DNA damage.We next
addressed whether the association between JMJD5 and p53 would
change after DNA damage. After adriamycin treatment, p53 and its
target gene p21 levels were upregulated as expected, whereas the
expression of JMJD5 remained unchanged (Fig. 4A). However, a reduced
associationwas found between JMJD5 and p53 in response to adriamycin,
particularly after 6 h treatment (Fig. 4B). Similar reduction pattern
was also observed after treatment with N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG), another DNA damaging agent, suggesting
that it is a general response to DNA damage (Fig. 4C). The subcellular
localization analysis revealed that adriamycin promoted nuclear
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Furthermore, we also found that p53 was accumulated, however JMJD5
was diminished, in the chromatin-bound fraction after adriamycin
exposure (Fig. 4E), which is consistent with the ﬁndings of reduced
association between JMJD5 and p53 after DNA damage.Fig. 1. JMJD5 negatively regulates the expression of CDKN1A (p21), and inﬂuences cell cycle prog
(qPCR) was used to assess the relative mRNA levels of TP53 and CDKN1A after JMJD5 knockdown
(Ctr siRNA). *P b 0.05 and **P b 0.01, comparedwith control. (B)Western blot analysis of the expre
was used as loading control. (C) Activity of a p21 luciferase reporter construct in HEK293T cells
(Ctr siRNA). (D) Subcellular localization of p53 in A549 cells. Cells were immunostained with an
images (merge) are zoomed in right panels (zoom). The line proﬁles of p53 and DAPI signals w
ﬂuorescence intensity of (D) was analyzed by the ZEN 2011 Histogram program from 15 indepen
represents as percentage of MFI [N/(N + C)]. **P b 0.01, compared with control (Ctr siRNA). (
H1299 cells. *P (or #P) b 0.05 and **P (or ##P) b 0.01, compared with control (Ctr siRNA). (G) Ce
EV represents empty vector.3.4. JMJD5modulates p53 target gene regulation by affecting its DNA binding
ability
To further understand the role of JMJD5 in p53 mediated gene
regulation, we examined the expression level of several well-knownression and proliferation in p53-proﬁcient lung cancer cells. (A) Quantitative real-time PCR
or overexpression in A549 and H1299 cells. A siRNA targeting luciferase was used as control
ssion level of JMJD5, p53, and p21 after JMJD5 siRNA treatment in A549 andH1299 cells. Actin
with the treatment of JMJD5 or p53 siRNA. *P b 0.05 and **P b 0.01, compared with control
ti-p53 (green). The nucleus is marked with DAPI (blue). Framed areas shown in the merge
ere measured by ZEN 2011 (Carl Zeiss) software. Scale bar represents 10 μm. (E) The mean
dent cells from three preparations. The relative ﬂuorescence intensity of p53 in the nucleus
F) Cell proliferation was monitored by cell counting after JMJD5 knockdown in A549 and
ll cycle analysis by ﬂow cytometry after JMJD5 knockdown or overexpression in A549 cells.
Fig. 2. JMJD5 associates with p53. Flag-tagged JMJD5 or Myc-tagged p53 was coexpressed in HEK293T cells. After anti-Flag (A) or anti-Myc (B) immunoprecipitation (IP), coprecipitated
proteinswere detected by indicated antibodies. (C) Complex formation of endogenous JMJD5 and p53 in A549 lung cancer cells. Cell extracts were subjected to immunoprecipitationwith
IgG or anti-p53 antibody. Coprecipitated JMJD5 was revealed by immunoblotting. (D) GST pull-down assays were performed with puriﬁed Flag–JMJD5 from A549 cells and GST alone or
GST–p53 fusion protein expressed in bacterial cells. Ponceau S staining indicated GST or GST–p53.
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cells and p53-deﬁcient H1299 cells. In addition to CDKN1A, P53R2,
MDM2, GADD45, SFN and NOXA were also signiﬁcantly upregulated in
A549 cells. However, the increased expression of these genes was
dramatically reduced or abolished in H1299 cells, indicating a p53-
dependent regulation (Fig. 5A). Interestingly, two p53 target genes,
PUMA and PIG3, showed comparable induction after JMJD5 knockdown
in the two cell lines, suggesting that a p53-independentmechanismwas
also involved. Meanwhile, JMJD5 mutants were ectopically expressed in
A549 cells (Fig. 5B). The wild type and the catalytically inactive mutant
of JMJD5 (H321A/D323A) showed an inhibitory effect on p53 down-
stream gene expression, while the JMJD5 (1–151) fragment without
p53 binding activity and the NLS mutant JMJD5–K166A (a dramatically
impaired nuclear localization form of JMJD5, thus has reduced enzyme
activity to nuclear substrates [12]) presented no transcriptional repres-
sion of p53. The results indicate that the p53 binding ability and nuclear
localization of JMJD5 are essential to its negative regulation of p53, and
the enzymatic activity of JMJD5 seems not involved in this modulation.
We next evaluated gene expression changes under DNA damage. As
expected, CDKN1A was strongly induced upon adriamycin treatment,
and further enhanced after incorporating with JMJD5 ablation
(Fig. 5C). Similar results were found in other p53-dependent target
genes, such as P53R2 (Fig. 5C and data not shown). Then we addressed
whether JMJD5 executes its function through affecting p53 binding
toward DNA. Using chromatin immunoprecipitation (ChIP) and
real-time polymerase chain reaction (PCR), we found a signiﬁcantly
increased recruitment of p53 to the p53 responsive elements (REs) in
CDKN1A and P53R2 gene promoter after JMJD5 silencing in A549 cells
(Fig. 5D and E). Furthermore, after adriamycin treatment, we observed
the enhanced binding of p53 and the decreased binding of JMJD5 at the
p53-REs of CDKN1A and P53R2 promoter (Fig. 5F and G). H3K36me2,
the targeting histone modiﬁcation of JMJD5, only presented a slight
increase at the−2.3 kb p53-RE (RE1) of CDKN1A. Altogether, our data
illustrate that JMJD5 negatively modulates p53 transcriptional activity
through affecting the DNA binding ability of p53.3.5. JMJD5 inﬂuences cell cycle and cell proliferation after DNA damage in a
p53-dependent manner
p53 restricts aberrant cell growth in response to DNA damage by
triggering cell-cycle arrest or apoptosis. To address the involvement of
JMJD5 in these events, we ectopically overexpressed JMJD5 in A549
cells followed by control or adriamycin treatment. A signiﬁcant relief
of cell-cycle arrest was observed in adriamycin treated cells after over-
expression of JMJD5 (Figs. 6A and S2A). In contrast, no effects were
found in p53-negative H1299 cells, indicating that JMJD5 affects cell
cycle mainly through p53 signaling pathway (Figs. 6B and S2B). For
apoptosis, however, we could not detect impacts of JMJD5 neither in
A549 nor in H1299 cells (Fig. 6A and B, and cleaved-caspase 3 and
TUNEL data not shown). Then we examined whether the enzymatic
activity of JMJD5 was needed for its cell cycle regulatory function. The
catalytically inactive mutant JMJD5–H321A/D323A and NLS mutant
JMJD5–K166A were employed. In contrast to the signiﬁcant reduction
of G2/M fraction in the JMJD5–H321A/D323A expressing cells, an
unrelieved G2/M arrest upon adriamycin treatment was found in cells
with the NLS mutant (Fig. 6A). These ﬁndings suggest that the correct
nuclear localization rather than the enzymatic activity of JMJD5 was
largely required in its cell cycle regulation. Moreover, JMJD5's effect on
cell proliferation was also evaluated. Adriamycin treatment caused
impairment of cell growth in control A549 cells, and this was even more
severe upon JMJD5 depletion (Fig. 6C). However, no signiﬁcant inﬂuence
of JMJD5 knockdownwas detected in p53-null H1299 cells. These results
indicate that JMJD5 promotes cell cycle progression and cell growth in a
p53-dependent manner, in particular upon DNA damage.4. Discussion
Unlikemost of other family members employing additional DNA- or
protein-binding domains to facilitate their functions, JMJD5 only
contains the enzymatic JmjC domain in its C-terminus [2]. Thus, it raises
Fig. 3. Protein domains involved in JMJD5–p53 interaction. Schematic representation of the Flag-tagged p53 (A, top panel) and Myc-tagged JMJD5 (B, top panel) constructs. FL represents
full-length p53 or JMJD5. (A, bottom panel) Flag-tagged p53 fragments were coexpressed with Myc–JMJD5 in HEK293T cells. After anti-Flag immunoprecipitation, coprecipitated JMJD5
was revealed by immunoblotting. Myc-tagged JMJD5 fragments (B, bottom panel) or mutants (C) were coexpressed with the DNA-binding domain of Flag–p53 (101–300) in HEK293T
cells. After anti-Flag immunoprecipitation, coprecipitated JMJD5 fragments or mutants were revealed by immunoblotting. (D) Prediction of the interaction of JMJD5 (PDB: 4GJY) with
the DBD of p53 (PDB: 2FEJ). In silico docking was performed using ClusPro 2.0 server (http://cluspro.bu.edu/login.php). The DNA binding region of p53 DBD comprises the major (loop
L1 and helix H2) and minor groove (loops L2 and L3) binding surfaces.
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which it binds. In fact, two recent reports support this hypothesis:
JMJD5 associated with osteoclastogenic transcription factor NFATc1 and
the critical tumor metabolism regulator PKM2 to play an important role
in osteoclastogenesis and cancer metabolism [9,10]. In this investigation,
we uncover a functional interaction between JMJD5 and the tumor
suppressor p53. With this association, JMJD5 negatively regulates the
transcriptional activity of p53, resulting in cell cycle control and prolifera-
tion modulation under both normal and DNA damage conditions in lung
cancer cells.Wedeﬁned JMJD5 as a repressor of p53based on several lines
of evidence: 1) JMJD5 knockdown increased the expression of most p53
target genes only in p53-positive cells; 2) depletion of JMJD5 promoted
p53 accumulation at the responsive elements of downstream genes;
3) uponDNAdamage, the association of p53with JMJD5was signiﬁcantlyreduced; and 4) p53 binding was enhanced, whereas JMJD5 occupancy
was diminished at the target genes of p53 after DNA damage stimuli.
Our data demonstrate that the DNA-binding domain (DBD) of p53
mediates the JMJD5–p53 association. P53DBDbears themajority ofmu-
tations in human cancers and is crucial for the activation of downstream
genes [28]. Many important cofactor proteins have been identiﬁed to
interact with the DBD of p53, such as MDM2 (murine double minute
2), BRCA2 (breast cancer type 2 susceptibility protein) and HIF-1α
(hypoxia-inducible factor 1-α), resulting in ﬁne-tuned regulation of
p53 activity or stability [29]. Our ﬁndings of JMJD5 associating with
the core DBD and acting as a repressor of p53 indicated that JMJD5
may interfere with the p53–DNA binding ability, therefore inﬂuence
its activation of target genes. With in silico docking analysis, we further
predicted the interaction between JMJD5 and p53 DBD. The results of
Fig. 4.The association between JMJD5 and p53 afterDNAdamage inA549 cells. (A)Western blot analysis of the expression level of JMJD5, p53, and p21 after 1 μMadriamycin treatment for
indicated hours. GAPDH was used as loading control. (B) Cell lysates were subjected to immunoprecipitation with IgG or anti-p53 antibody after 1 μM adriamycin treatment (Adr) for
indicated hours. Coprecipitated JMJD5 was revealed by immunoblotting. DMSO was used as solvent control (Ctr). (C) A549 cells were treated with 1 μM adriamycin (Adr) or 5 μM
MNNG for 6 h and immunoprecipitation was performed as (B). DMSO was used as solvent control (Ctr). (D) Analysis of the mean ﬂuorescence intensity of p53 and JMJD5 in the cytosol
and nucleus after 1 μM adriamycin (Adr) treatment. Mean values from 15 independent cells from three preparations were determined. *P b 0.05 and **P b 0.01, compared with DMSO.
(E) Chromatin-enriched fraction (P) or soluble nuclear fraction (S) were collected after 1 μM or 2 μM adriamycin treatment and the level of p53 and JMJD5 was detected. H3 and
GAPDH were used as loading control for chromatin-enriched fraction and soluble nuclear fraction, respectively. DMSO was used as solvent control (Ctr).
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within or near theDNAbinding surface of p53DBD, thusmay cause struc-
tural obstacles preventing interaction of p53with speciﬁcDNAsequences.
Further studies, such as crystal structure analysis, are required to conﬁrm
and characterize the JMJD5–p53 complex at the molecular level.
On the other hand, the sequence between NLS and JmjC domain of
JMJD5, but not the JmjC demethylase domain, is required for JMJD5–p53
interaction. Combinedwith our further evidences that JMJD5has no effect
on p53 methylation in the in vivo and in vitro assays, we speculate that
JMJD5 is not a demethylase of p53. Nonetheless, the possibility that
JMJD5 demethylates p53 methylation cannot be excluded because such
reaction could occur under speciﬁc conditions or at a level below our
detection.
Upon DNA damage, we discovered that the interaction between
JMJD5 and p53 was decreased. One possible mechanism for this effectcould be the altered intracellular localization of these two proteins.
Our further results conﬁrmed that p53 accumulated in the nucleus,
while JMJD5 became more cytoplasmically localized following DNA
damage. Another possible explanation could be the regulation of
post-translational modiﬁcations (PTMs). It has been reported that both
p53 and its binding partners can be modiﬁed (such as phosphorylation)
to induce a conformational change in protein structure or a direct inter-
ference of the interaction [30–32]. Therefore, it would be interesting to
examinewhether such a PTMmechanism is also involved in JMJD5–p53
regulation in the future.
Among the p53 target genes we assessed, CDKN1Awas signiﬁcantly
induced after JMJD5 depletion. As a potent cell cycle inhibitor, p21
(CDKN1A) is important in promoting cell-cycle arrest in response to
various stimuli, and thus plays a critical role in cell proliferation and
cancer development. Previous studieswith JMJD5 knockoutmice showed
Fig. 5. JMJD5negatively regulates the activation of p53 target genes. (A) The relativemRNA level of p53 target geneswas analyzedbyqPCRafter JMJD5 siRNA treatment inA549 andH1299
cells. *Pb 0.05 and **P b 0.01, comparedwith control inA549 cells. #P b 0.05, comparedwith control inH1299 cells. (B) qPCR analysis ofCDKN1A and P53R2mRNA level after JMJD5 full-length or
mutants overexpression in A549 cells. EV represents empty vector. *P b 0.05 and **P b 0.01, comparedwith control. (C) qPCR (top panel) andWestern blot analysis (bottom panel) of CDKN1A
and P53R2 in 1 μMadriamycin (Adr, 6 h) and JMJD5 siRNA treated A549 cells. DMSOwas used as solvent control. *P b 0.05 and **P b 0.01, comparedwith control. (D) The p53 binding sites (RE)
and their core sequences are shown in the CDKN1A and P53R2promoter. Their location relative to the TSS is indicated. (E) ChIP assayswere performed to detect p53 recruitment to CDKN1A and
P53R2 P53-REs in A549 cells transfected with control, p53 or JMJD5 siRNA. *P b 0.05 and **P b 0.01, compared with control. ChIP assays of CDKN1A (F) and P53R2 (G) P53-REs with indicated
antibodies inA549 cells after treatmentwith 1 μMadriamycin (Adr) for 6h. *P b 0.05 and **P b 0.01, comparedwith control. All the ChIP resultswerenormalized to IgG controls and shownas an
average fold change in enrichment. DMSO was used as solvent control.
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whichmayormaynot dependonp53 activity [7,8].Wehere demonstrate
that JMJD5 can also negatively modulate the expression of p21 in human
cancer cells, however, largely by interfering the transcriptional activity of
p53. Our ChIP data further showed that the binding of JMJD5 to CDKN1A
promoter decreased upon DNA damage, suggesting that JMJD5 functions
as an important repressor for the steady-state expression of p21.Another highly induced gene after JMJD5 silencing is P53R2, which
contributes to DNA repair by supplying nucleotides. Generally, the tran-
scriptional induction of p53R2 in mRNA is quite slow comparing to
other rapidly induced p53 target genes, such as CDKN1A [33,34]. By con-
trast, p53R2 employs a way of ATM-mediated phosphorylation to
quickly maintain its protein stability from degradation in response to
DNA damage [35]. Therefore, the ﬁnding of P53R2 as one of the major
Fig. 6. JMJD5 affects cell cycle progression and cell proliferationwith orwithout DNAdamage
in a p53-dependent manner. (A) A549 cells were transfected with empty vector (EV),
full-length JMJD5, catalytically inactive mutant JMJD5–H321A/D323A and NLS mutant
JMJD5–K166A followed by 1 μM adriamycin treatment (Adr) for 24 h. Cell cycles were
then determined by ﬂow cytometry. (B) Cell cycle analysis of H1299 cells transfected with
emptyvector (EV)or full-length JMJD5plus 1 μMadriamycin (Adr) or 5 μMMNNG treatment
for 24 h. Flow cytometry was used for detection. (C) Cell proliferation wasmonitored by cell
counting after JMJD5 knockdown and 1 μM adriamycin (Adr) treatment in A549 and H1299
cells. *P b 0.05, compared with control.
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quite interesting and may imply an important role of JMJD5 in DNA
repair. In fact, JMJD5 was initially characterized as a putative tumor
suppressor thatmight function onDNAmismatch repair [36]. Therefore,
the involvement of JMJD5 in DNA damage repair and the underlying
mechanisms should be further studied in the future.
Taken together, our ﬁndings demonstrate that JMJD5, a demethylase/
hydroxylase, forms complex with p53 and contributes to cell cycle and
cell growth promotion mainly through a negative regulation of p53
transcriptional activity. Its inhibition, potentially by small molecule
drugs, could be beneﬁcial in the treatment of cancer. Further studies are
required to unravel whether other p53 controlling tumor suppressor
functions, such as DNA repair, are modulated by JMJD5.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.05.026.Conﬂict of interest
The authors declare that there is no conﬂict of interest.Acknowledgements
This work was supported by the National Natural Science Foundation
of China (Grant Nos. 81171885 and 81472543); and the Zhejiang
Provincial Natural Science Foundation of China (Grant Nos.
LY14H160024, Y2110217 and LY13H160001).References
[1] E.L. Greer, Y. Shi, Histone methylation: a dynamic mark in health, disease and
inheritance, Nat. Rev. Genet. 13 (2012) 343–357.
[2] S.M. Kooistra, K. Helin, Molecular mechanisms and potential functions of histone
demethylases, Nat. Rev. Mol. Cell Biol. 13 (2012) 297–311.
[3] M.E. Cockman, J.D. Webb, P.J. Ratcliffe, FIH-dependent asparaginyl hydroxylation of
ankyrin repeat domain-containing proteins, Ann. N. Y. Acad. Sci. 1177 (2009) 9–18.
[4] C.J. Webby, A. Wolf, N. Gromak, M. Dreger, H. Kramer, B. Kessler, M.L. Nielsen, C.
Schmitz, D.S. Butler, J.R. Yates III, C.M. Delahunty, P. Hahn, A. Lengeling, M. Mann,
N.J. Proudfoot, C.J. Schoﬁeld, A. Bottger, Jmjd6 catalyses lysyl-hydroxylation of
U2AF65, a protein associated with RNA splicing, Science 325 (2009) 90–93.
[5] D.A. Hsia, C.G. Tepper, M.R. Pochampalli, E.Y. Hsia, C. Izumiya, S.B. Huerta, M.E.
Wright, H.W. Chen, H.J. Kung, Y. Izumiya, KDM8, a H3K36me2 histone demethylase
that acts in the cyclin A1 coding region to regulate cancer cell proliferation, Proc.
Natl. Acad. Sci. U. S. A. 107 (2010) 9671–9676.
[6] M.A. Jones, M.F. Covington, L. DiTacchio, C. Vollmers, S. Panda, S.L. Harmer, Jumonji
domain protein JMJD5 functions in both the plant and human circadian systems,
Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 21623–21628.
[7] S. Oh, R. Janknecht, Histone demethylase JMJD5 is essential for embryonic
development, Biochem. Biophys. Res. Commun. 420 (2012) 61–65.
[8] A. Ishimura, K. Minehata, M. Terashima, G. Kondoh, T. Hara, T. Suzuki, Jmjd5, an
H3K36me2 histone demethylase, modulates embryonic cell proliferation through
the regulation of Cdkn1a expression, Development 139 (2012) 749–759.
[9] M.Y. Youn, A. Yokoyama, S. Fujiyama-Nakamura, F. Ohtake, K. Minehata, H. Yasuda,
T. Suzuki, S. Kato, Y. Imai, JMJD5, a Jumonji C (JmjC) domain-containing protein,
negatively regulates osteoclastogenesis by facilitating NFATc1 protein degradation,
J. Biol. Chem. 287 (2012) 12994–13004.
[10] H.J.Wang, Y.J. Hsieh,W.C. Cheng, C.P. Lin, Y.S. Lin, S.F. Yang, C.C. Chen, Y. Izumiya, J.S. Yu,
H.J. Kung, W.C. Wang, JMJD5 regulates PKM2 nuclear translocation and reprograms
HIF-1alpha-mediated glucose metabolism, Proc. Natl. Acad. Sci. U. S. A. 111 (2014)
279–284.
[11] P.A. Del Rizzo, S. Krishnan, R.C. Trievel, Crystal structure and functional analysis of
JMJD5 indicate an alternate speciﬁcity and function, Mol. Cell. Biol. 32 (2012)
4044–4052.
[12] X. Huang, L. Zhang, H. Qi, J. Shao, J. Shen, Identiﬁcation and functional implication of
nuclear localization signals in the N-terminal domain of JMJD5, Biochimie 95 (2013)
2114–2122.
[13] H. Zhu, S. Hu, J. Baker, JMJD5 regulates cell cycle and pluripotency in human embryonic
stem cells, Stem Cells 32 (2014) 2098–2110.
[14] F. Murray-Zmijewski, E.A. Slee, X. Lu, A complex barcode underlies the heterogeneous
response of p53 to stress, Nat. Rev. Mol. Cell Biol. 9 (2008) 702–712.
[15] A. Scoumanne, X. Chen, Protein methylation: a new mechanism of p53 tumor
suppressor regulation, Histol. Histopathol. 23 (2008) 1143–1149.
[16] X. Shi, I. Kachirskaia, H. Yamaguchi, L.E. West, H. Wen, E.W. Wang, S. Dutta, E.
Appella, O. Gozani, Modulation of p53 function by SET8-mediated methylation at
lysine 382, Mol. Cell 27 (2007) 636–646.
[17] S. Chuikov, J.K. Kurash, J.R. Wilson, B. Xiao, N. Justin, G.S. Ivanov, K. McKinney, P.
Tempst, C. Prives, S.J. Gamblin, N.A. Barlev, D. Reinberg, Regulation of p53 activity
through lysine methylation, Nature 432 (2004) 353–360.
[18] J. Huang, L. Perez-Burgos, B.J. Placek, R. Sengupta, M. Richter, J.A. Dorsey, S. Kubicek,
S. Opravil, T. Jenuwein, S.L. Berger, Repression of p53 activity by Smyd2-mediated
methylation, Nature 444 (2006) 629–632.
[19] J. Huang, R. Sengupta, A.B. Espejo, M.G. Lee, J.A. Dorsey, M. Richter, S. Opravil, R.
Shiekhattar, M.T. Bedford, T. Jenuwein, S.L. Berger, p53 is regulated by the lysine
demethylase LSD1, Nature 449 (2007) 105–108.
[20] T.D. Kim, S. Shin, W.L. Berry, S. Oh, R. Janknecht, The JMJD2A demethylase regulates
apoptosis and proliferation in colon cancer cells, J. Cell. Biochem. 113 (2012)
1368–1376.
[21] C.I. Ene, L. Edwards, G. Riddick, M. Baysan, K.Woolard, S. Kotliarova, C. Lai, G. Belova,M.
Cam, J.Walling,M. Zhou,H. Stevenson,H.S. Kim,K. Killian, T. Veenstra, R. Bailey,H. Song,
W. Zhang,H.A. Fine,Histonedemethylase JumonjiD3 (JMJD3) as a tumor suppressor by
regulating p53 protein nuclear stabilization, PLoS One 7 (2012) e51407.
[22] T.D. Kim, S. Oh, S. Shin, R. Janknecht, Regulation of tumor suppressor p53 and
HCT116 cell physiology by histone demethylase JMJD2D/KDM4D, PLoS One 7
(2012) e34618.
[23] K.H. Lee, J.W. Park, H.S. Sung, Y.J. Choi, W.H. Kim, H.S. Lee, H.J. Chung, H.W. Shin, C.H.
Cho, T.Y. Kim, S.H. Li, H.D. Youn, S.J. Kim, Y.S. Chun, PHF2 histone demethylase acts
as a tumor suppressor in association with p53 in cancer, Oncogene 34 (2015)
2897–2909.
2295X. Huang et al. / Biochimica et Biophysica Acta 1853 (2015) 2286–2295[24] W. Liu, B. Tanasa, O.V. Tyurina, T.Y. Zhou, R. Gassmann,W.T. Liu, K.A. Ohgi, C. Benner,
I. Garcia-Bassets, A.K. Aggarwal, A. Desai, P.C. Dorrestein, C.K. Glass, M.G. Rosenfeld,
PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle
progression, Nature 466 (2010) 508–512.
[25] D. Kozakov, D. Beglov, T. Bohnuud, S.E. Mottarella, B. Xia, D.R. Hall, S. Vajda, How
good is automated protein docking? Proteins 81 (2013) 2159–2166.
[26] J.M. Canadillas, H. Tidow, S.M. Freund, T.J. Rutherford, H.C. Ang, A.R. Fersht, Solution
structure of p53 core domain: structural basis for its instability, Proc. Natl. Acad. Sci.
U. S. A. 103 (2006) 2109–2114.
[27] Y. Cho, S. Gorina, P.D. Jeffrey, N.P. Pavletich, Crystal structure of a p53 tumor
suppressor–DNA complex: understanding tumorigenic mutations, Science 265
(1994) 346–355.
[28] W.A. Freed-Pastor, C. Prives, Mutant p53: one name, many proteins, Genes Dev. 26
(2012) 1268–1286.
[29] L. Collavin, A. Lunardi, G. Del Sal, p53-family proteins and their regulators: hubs and
spokes in tumor suppression, Cell Death Differ. 17 (2010) 901–911.
[30] S. Shieh, M. Ikeda, Y. Taya, C. Prives, DNA damage-induced phosphorylation of p53
alleviates inhibition by MDM2, Cell 91 (1997) 325–334.[31] X. Deng, F. Gao, T. Flagg, J. Anderson, W. May, Bcl2's ﬂexible loop domain regulates
p53 binding and survival, Mol. Cell. Biol. 26 (2006) 4421–4434.
[32] Q. Tong, S. Mazur, H. Arano, S. Rothbart, D. Kuznetsov, G. Cui,W. Liu, Y. Gete, B. Klein,
L. Jenkins, G. Mer, A. Kutateladze, B. Strah, M. Groudine, E. Appella, T. Kutateladze,
An acetyl–methyl switch drives a conformational change in p53, Structure 23
(2015) 322–331.
[33] P. Nordlund, P. Reichard, Ribonucleotide reductases, Annu. Rev. Biochem. 75 (2006)
681–706.
[34] H. Tanaka, H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei, Y.
Nakamura, A ribonucleotide reductase gene involved in a p53-dependent
cell-cycle checkpoint for DNA damage, Nature 404 (2000) 42–49.
[35] L. Chang, B. Zhou, S. Hu, R. Guo, X. Liu, S.N. Jones, Y. Yen, ATM-mediated serine 72
phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein
against MDM2 to DNA damage, Proc. Natl. Acad. Sci. U. S. A. 105 (2008)
18519–18524.
[36] T. Suzuki, K. Minehata, K. Akagi, N.A. Jenkins, N.G. Copeland, Tumor suppressor gene
identiﬁcation using retroviral insertional mutagenesis in Blm-deﬁcient mice, EMBO
J. 25 (2006) 3422–3431.
